ACPA-positive versus ACPA-negative rheumatoid arthritis: two distinct erosive disease entities on radiography and ultrasonography.


Journal

Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 04 09 2019
accepted: 03 12 2019
pubmed: 14 12 2019
medline: 1 4 2021
entrez: 14 12 2019
Statut: ppublish

Résumé

The objective of this study is to assess the prevalence, localization, and severity of bone erosions on radiography (RX) and ultrasonography (US) according to ACPA status in patients with rheumatoid arthritis (RA). 78 patients with ACPA-positive (ACPA+) RA and 30 patients with ACPA-negative (ACPA-) RA fulfilling the ACR 1987 and/or ACR/EULAR 2010 criteria were consecutively included. On RX, a modified Sharp erosion score (SHSe) was evaluated by two blinded readers and one adjudicator for discordant cases (number of eroded joints ≤ three). On US, erosions were scored on six bilateral joints (MCP2, 3, 5; MTP2, 3, 5) with a four-point scale to calculate the total US score for erosions (USSe). The mean total SHSe and USSe were 3.7 and 4.4 times higher in the ACPA+ group than in the ACPA- group, respectively (P < 0.001). On both RX and US, the most discriminating joint between the two groups was MTP5, especially in cases with bilateral erosion. Based on multivariate analyses, ACPA + status was associated with erosive RA on RX according to the EULAR 2013 definition criteria [OR 4.4 (95% CI 1.2-16.4)], and on US according to the following two definitions: the presence of at least two eroded joint facets [OR 3.7 (95% CI 1.4-9.9)] or at least one grade 2 joint facet erosion [OR 9.0 (95% CI 2.8-28.4)]. Compared to ACPA- RA, ACPA + RA is associated independently with more severe erosive disease on RX and US. Both US and RX bilateral erosions in MTP5 joints are highly discriminant for ACPA + RA patients (97.8% in US and 100% in RX).

Identifiants

pubmed: 31834475
doi: 10.1007/s00296-019-04492-5
pii: 10.1007/s00296-019-04492-5
doi:

Substances chimiques

Anti-Citrullinated Protein Antibodies 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

615-624

Références

Ann Rheum Dis. 2017 Jan;76(1):112-118
pubmed: 27117699
J Clin Invest. 2012 May;122(5):1791-802
pubmed: 22505457
Arthritis Rheum. 2004 Feb;50(2):380-6
pubmed: 14872479
Rheumatology (Oxford). 2014 Jun;53(6):1100-7
pubmed: 24501246
Scand J Rheumatol. 2000;29(3):170-3
pubmed: 10898069
Ann Rheum Dis. 2010 Sep;69(9):1580-8
pubmed: 20699241
Reumatol Clin. 2014 Sep-Oct;10(5):278-82
pubmed: 24725610
Semin Arthritis Rheum. 2006 Dec;36(3):182-8
pubmed: 17045630
J Rheumatol. 2005 May;32(5):778-86
pubmed: 15868609
J Rheumatol. 2013 Aug;40(8):1259-67
pubmed: 23378461
Ann Rheum Dis. 2006 May;65(5):595-600
pubmed: 16192290
J Rheumatol. 2016 Jan;43(1):12-21
pubmed: 26628596
Clin Rheumatol. 2008 Aug;27(8):983-9
pubmed: 18259687
Annu Rev Immunol. 2008;26:651-75
pubmed: 18173373
Ann Rheum Dis. 2013 Apr;72(4):479-81
pubmed: 23378540
Ann Rheum Dis. 2004 Sep;63(9):1090-5
pubmed: 15308518
Skeletal Radiol. 2007 Feb;36(2):123-8
pubmed: 17033852
Ann Rheum Dis. 2004 Sep;63(9):1085-9
pubmed: 15308517
Rheumatology (Oxford). 2015 Oct;54(10):1797-805
pubmed: 25972391
Rheumatology (Oxford). 2011 Jun;50(6):1137-47
pubmed: 21278073
Scand J Rheumatol. 2008 Sep-Oct;37(5):337-42
pubmed: 18609264
Nat Rev Rheumatol. 2012 Nov;8(11):656-64
pubmed: 23007741
Clin Rheumatol. 2017 Jul;36(7):1487-1492
pubmed: 28578492
Ann Rheum Dis. 2011 Jun;70(6):1173-4
pubmed: 20956407
Ann Rheum Dis. 2015 May;74(5):897-903
pubmed: 24445255
Arthritis Rheum. 2000 Dec;43(12):2762-70
pubmed: 11145034
Curr Rheumatol Rep. 2013 Oct;15(10):366
pubmed: 23955066
Arthritis Res Ther. 2006;8(2):R52
pubmed: 16519793
Rheumatol Int. 2011 May;31(5):617-22
pubmed: 20049446
J Rheumatol. 1995 Sep;22(9):1792-6
pubmed: 8523365
Clin Chem Lab Med. 2014 Jun;52(6):779-90
pubmed: 24445240
Ann Rheum Dis. 2005 Oct;64(10):1427-30
pubmed: 15800010
Rheumatology (Oxford). 1999 Oct;38(10):941-7
pubmed: 10534543
Bioessays. 2003 Nov;25(11):1106-18
pubmed: 14579251
J Rheumatol. 2000 Jan;27(1):261-3
pubmed: 10648051
Int J Rheumatol. 2015;2015:728610
pubmed: 25821469

Auteurs

Julien Grosse (J)

Department of Rheumatology, University Hospital of Nancy, 54500, Vandoeuvre-lès-Nancy, France. j.grosse@chru-nancy.fr.

Edem Allado (E)

Department of Rheumatology, University Hospital of Nancy, 54500, Vandoeuvre-lès-Nancy, France.

Camille Roux (C)

Department of Rheumatology, University Hospital of Nancy, 54500, Vandoeuvre-lès-Nancy, France.

Audrey Pierreisnard (A)

Department of Rheumatology, Academic Hospital Pitié-Salpêtrière, 75013, Paris, France.

Marion Couderc (M)

Department of Rheumatology, University Hospital of Clermont-Ferrand, 63000, Clermont-Ferrand, France.

Isabelle Clerc-Urmes (I)

Platform of Clinical Research Support PARC (MDS Unity), University Hospital of Nancy, 54500, Vandoeuvre-lès-Nancy, France.

Thomas Remen (T)

Platform of Clinical Research Support PARC (MDS Unity), University Hospital of Nancy, 54500, Vandoeuvre-lès-Nancy, France.

Éliane Albuisson (É)

Platform of Clinical Research Support PARC (MDS Unity), University Hospital of Nancy, 54500, Vandoeuvre-lès-Nancy, France.

Marcelo De Carvalho-Bittencourt (M)

Biology and Immunology Laboratory, University Hospital of Nancy, 54500, Vandoeuvre-lès-Nancy, France.

Isabelle Chary-Valckenaere (I)

Department of Rheumatology, University Hospital of Nancy, 54500, Vandoeuvre-lès-Nancy, France.
INSERM, CIC-EC CIE6, Nancy, France University Hospital of Nancy, Epidemiology and Clinical Evaluation, 54500, Vandoeuvre-lès-Nancy, France.

Damien Loeuille (D)

Department of Rheumatology, University Hospital of Nancy, 54500, Vandoeuvre-lès-Nancy, France.
INSERM, CIC-EC CIE6, Nancy, France University Hospital of Nancy, Epidemiology and Clinical Evaluation, 54500, Vandoeuvre-lès-Nancy, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH